Babjuk M. European Urology Supplements. Volume 10, Issue 3, May 2011, Pages e8–e11. IF: 2.139
Abstract:
Context: Transurethral resection (TUR) is a critical step in the management of non-muscle-invasive bladder cancer (NMIBC). Because of the high risk of tumour persistence and understaging, the routine second TUR performed after 2–6 wk is recommended by European Association of Urology guidelines in all patients with T1 or high-grade NMIBC. Objective: To summarise arguments that support the recommendation of routine second TUR in all patients with T1 or high-grade NMIBC. Evidence acquisition: Data and arguments were retrieved from a critically selected list of articles and abstracts dealing with the surgical treatment of NMIBC. Evidence synthesis: In patients with T1 tumours, the risk of tumour persistence and tumour understaging detected by the second TUR was 33–78% and 2–28%, respectively. The pathologic finding achieved by second TUR can modify the treatment strategy in a significant number of patients. Correct staging in NMIBC enables the selection of the optimal treatment modality and improves results. Conclusions: The second TUR confirmed the presence of residual cancer and tumour understaging in a significant number of T1 and high-grade tumours. This is a strong argument that supports the recommendation of second TUR in patients with T1 or high-grade NMIBC.
-mk-
